OrthoPediatrics Q3 revenue up 39% to $35M; cuts FY2022 revenue guidance to $124-125M

ORTHOPEDIATRICS CORP

2022-Q3 EPS reported $0.43 revenue$91,295,000

Revenue $35.0M (+39% YoY); organic growth ~22% excluding MD Ortho and Pega Medical contributions of $4.4M.
Net income $18.5M ($0.87 diluted EPS) vs net loss ($2.2M) in Q3 2021, includes $23M fair value adjustment.
FY2022 revenue guidance lowered to $124-125M (from $127-130M); organic guidance $113-114M (15-16% growth).
Adjusted EBITDA $1.9M vs $0.5M in Q3 2021; cash and equivalents $121.6M with no debt drawn.
Company cites RSV infections and staffing shortages as September headwinds; Pega Medical acquisition closed in July.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ORTHOPEDIATRICS CORP reported third quarter ended September 30, 2022 results: revenue $35.0 million, net income $18.5 million, EPS $0.87 per diluted share.

Period: third quarter ended September 30, 2022
Revenue: $35.0 million
Net income: $18.5 million
EPS: $0.87 per diluted share
Result: reported results

Exact text from the filing

Total revenue for the third quarter of 2022 was $35.0 million, a 39% increase compared to $25.1 million for the same period last year.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ORTHOPEDIATRICS CORP reported full year 2022 results: revenue $124 million to $125 million. Guidance lowered.

Period: full year 2022
Revenue: $124 million to $125 million
Guidance: lowered
Result: guidance update

Exact text from the filing

For full year 2022, the Company now expects its full year revenue to be in the range of $124 million to $125 million, updated from its previous guidance range of $127 million to $130 million

View on SEC.gov

Browse all earnings releases →

ORTHOPEDIATRICS CORP filing history →

Source: SEC EDGAR

accession 0001425450-22-000101

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.